Prostate Cancer

David Albala, MD, discusses the key advantages of utilizing PSMA-PET screening in clinical practice for patients with prostate cancer.

Emmanuel Antonarakis, MD, discusses the different therapeutic agents that are available for patients with metastatic castration-resistant prostate cancer who display either somatic or germline mutations.

Neal Shore, MD, discusses the importance of incorporating genetic testing into treatment strategies for patients with prostate cancer.

David Albala, MD, discusses integrating PSMA-PET imaging into the clinic and determining which patients with prostate cancer are prime candidates.

Neal Shore, MD, FACS, highlights the effect of genetic testing on the treatment paradigm of prostate cancer and the evolving treatment landscape for metastatic castration resistant prostate cancer.

The Chemotherapy Foundation Symposium® returns to New York City for its 40th annual meeting with a 3-day program that will deliver the latest updates across the gamut of oncology care.

The FDA has approved leuprolide acetate injection for use in the palliative treatment of patients with advanced prostate cancer.

Stephanie Berg, DO, discusses two key clinical trials that have advanced the standard of care in metastatic hormone-sensitive prostate cancer.

Christopher Wee, MD discusses the current treatment landscape for nonmetastatic castration-resistant prostate cancer, and how the success of new diagnostic tools decreases the need for this classification.

PARP inhibitors have emerged as agents that generate improved oncological outcomes in select patient populations with metastatic castration-resistant prostate cancer.

Darolutamide plus androgen-deprivation therapy and docetaxel elicited an overall survival benefit over placebo plus ADT and docetaxel in Black and African American patients with metastatic hormone-sensitive prostate cancer similar to the benefit observed in the overall population of the ARASENS trial.

A regimen comprised of radiation and intermittent hormone therapy (HT) resulted in an improvement in progression-free survival in patients with oligometastatic prostate cancer, according to data from the phase 2 EXTEND trial.

The combination of cediranib and olaparib significantly improved radiographic progression-free survival compared with olaparib monotherapy in patients with metastatic castration-resistant prostate cancer.

Rahul Aggarwal, MD, discusses the rationale for investigating androgen deprivation therapy intensification in biochemically relapsed prostate cancer.

Neal Shore MD, FACS, discusses future clinical research focuses in prostate cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of Lutetium 177 vipivotide tetraxetan in combination with androgen deprivation therapy with or without androgen receptor pathway inhibition for the treatment of adult patients with progressive prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have been treated with AR pathway inhibition and taxane-based chemotherapy.

Advances in the understanding of the genomics and biological functions of prostate cancer have resulted in the emergence of several new classes of agents that have improved outcomes in men with prostate cancer, including metastatic hormone-sensitive prostate cancer.

The addition of talazoparib to enzalutamide produced a statistically significant and clinically meaningful improvement in radiographic progression-free survival vs enzalutamide plus placebo in previously untreated patients with metastatic castration-resistant prostate cancer, with or without homologous recombination repair gene mutations.

Single-agent rucaparib significantly improved radiographic progression-free survival vs chemotherapy or second-line androgen deprivation therapy in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer harboring BRCA or ATM mutations.

The FDA has accepted for review a new drug application for 18F-rhPSMA-7.3, an investigational radiohybrid PSMA-targeted PET imaging agent for diagnostic imaging of prostate cancer, according to an announcement from Blue Earth Diagnostics.

The addition of AZD4635 to durvalumab or oleclumab did not elicit significant responses in heavily pretreated patients with metastatic castration-resistant prostate cancer.

Helen Heng-Shan Moon, MD, discusses the future of care in prostate cancer.

The definitive treatment of prostate cancer has historically relied on whole-gland treatment.

Enzalutamide plus androgen deprivation therapy elicited significant improvements in radiographic progression-free survival and overall survival vs placebo in patients with metastatic hormone-sensitive prostate cancer.

The decline of prostate-specific antigen following treatment with lutetium Lu 177 vipivotide tetraxetan plus standard of care was linked with prolonged radiographic progression-free survival and overall survival in patients with progressive prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.